Biodesix, Inc. - BDSX STOCK NEWS

Biodesix, Inc. (BDSX) announced a private placement of 6,508,376 common shares on April 7, 2022, raising approximately $11.7 million in net proceeds. These funds will support term loan repayment and general corporate purposes. The company also executed a Third Amendment to its 2021 Term Loan, providing additional financial flexibility. The repayment plan includes $3.0 million in April 2022 and another $2.0 million potentially extending to September 30, 2022. Biodesix reaffirms its 2022 revenue guidance of $37.5 million to $39.5 million.

Biodesix, Inc. (BDSX) has published new data validating the GeneStrat NGS test in the peer-reviewed journal, Diagnostics. This study confirms the efficacy of liquid biopsy tests for detecting tumor markers, contributing to lung cancer diagnostics. Biodesix will present findings on both the GeneStrat ddPCR and NGS tests at the AACR Annual Meeting from April 8-13, 2022. The combination of droplet digital PCR and NGS techniques enhances testing for non-small cell lung cancer (NSCLC), improving treatment options with rapid results.

Biodesix, Inc. (BDSX) reported its fourth-quarter and fiscal year 2021 results, showing lung diagnostic revenue of $5.4 million and $18.7 million, up 48% and 49% year-over-year. Total revenue reached $7.2 million for Q4 and $54.5 million for the year. The company doubled its sales force, which fueled growth. Despite the challenges of the pandemic, Biodesix plans to launch the GeneStrat NGS™ test in January 2022. However, net losses increased significantly, totaling $13.3 million for Q4 and $43.2 million for the year.

Biodesix, Inc. (Nasdaq: BDSX) has entered a purchase agreement with Lincoln Park Capital Fund, LLC to issue and sell up to $50 million of its common stock over a 36-month period. The agreement allows Biodesix to sell stock at its discretion, with no upper limit on purchase price based on market conditions. Proceeds will support growth initiatives and corporate purposes. The company retains the right to terminate the agreement without penalty, and there are no short-selling provisions involved.

Biodesix (NASDAQ: BDSX) presented critical data on its Primary Immune Response (PIR) test at the IASLC 2022 Lung Cancer Meeting. The PIR test categorizes patients into PIR-Not Resistant and PIR-Resistant, predicting responses to immune checkpoint inhibitors (ICIs). Results indicated that the test could forecast survival outcomes (HR=2.36, p=0.02 at baseline; HR=3.53, p=0.001 after ICI initiation) and identify those prone to rapid onset of immune-related adverse events (HR=2.40, p=0.08). The test is expected to commercially launch in 2023.

Biodesix, a data-driven diagnostic solutions company focused on lung disease, announced that CEO Scott Hutton will present at Cowen’s 42nd Annual Healthcare Conference on March 8, 2022, at 2:50 PM ET. The presentation will be available for live webcast and replay on Biodesix's website. Biodesix develops innovative diagnostic tests to aid in lung disease management, leveraging AI and multi-omics technology to improve patient outcomes.

Biodesix (NASDAQ: BDSX) will announce its financial results for Q4 and full year 2021 on March 14, 2022, before market open. A conference call will follow at 8:30 AM ET to discuss these results and provide a business update. The company specializes in diagnostic solutions for lung diseases, offering eight non-invasive tests. Key products include the Nodify Lung risk assessment tests and IQLung cancer support tests, which deliver rapid results. Biodesix continues to innovate with AI-driven diagnostics and has responded to the pandemic with additional SARS-CoV-2 testing.

Biodesix, Inc. (NASDAQ: BDSX) announced its CEO was recognized as one of the Top 25 Biotech CEOs of 2022 by The Healthcare Technology Report. This acknowledgment reflects the CEO's leadership philosophy focusing on improving health outcomes. Under his guidance, Biodesix has expanded its role in lung disease diagnostics. The company offers innovative non-invasive tests and collaborates with leading biotech firms using AI to enhance diagnostic solutions. This recognition signifies the team's commitment to impacting patients with critical lung diseases.

Biodesix, Inc. (NASDAQ: BDSX) reported a strong 2021, with total revenue of $54.5 million, a 49% increase from $45.6 million in 2020. The fourth quarter revenue reached $7.2 million, including $6.8 million from core lung diagnostics, which rose by 22% year-over-year. Cash reserves stood at $32.7 million as of December 31, 2021. CEO Scott Hutton noted growth driven by new testing strategies and plans to enhance liquidity through additional capital options.